Read More

FDA declines to approve Lykos’ MDMA-based PTSD drug, requests additional trial

Lykos Therapeutics hit a major roadblock Friday in its bid to bring the first psychedelic-based therapy for post-traumatic stress disorder to market, as U.S. regulators rejected its application and called for additional research. The Food and Drug Administration issued a complete response letter for Lykos’ new drug application for its …